Immune checkpoint inhibitor (ICI) therapies targeting PD-1 [11] and PD-L1 have been shown to be effective against cancers at various sites, and a number of blocking antibodies are currently being tested for use in BC [12,13]. Here, CD274 is linked to cancer.